Document and Entity Information Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Short-term Investments Short-term investments Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net Inventory, Net Inventory Total Inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Right-of-use asset Finite-Lived Intangible Assets, Net Total Intangible assets, net Restricted Cash Restricted cash Other Long-term Investments Other long-term assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses and other current liabilities Accrued expenses and other current liabilities Deferred Revenue, Current Deferred revenue Operating Lease, Liability, Current Lease liability Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Deferred Revenue, Noncurrent Deferred royalty obligation Capital Lease Obligations, Noncurrent Lease liability, non-current Derivative Liability Derivative liability Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.001 par value: 120,000,000 shares authorized; 59,426,559 and 56,612,429 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock par value per share Preferred Stock, Shares Authorized Preferred stock, authorized Preferred Stock, Shares Issued Preferred stock, issued Preferred Stock, Shares Outstanding Preferred stock, outstanding Common Stock, Par or Stated Value Per Share Common stock, par value per share Common Stock, Shares Authorized Common stock, authorized Common Stock, Shares, Issued Common stock, issued Common Stock, Shares, Outstanding Common stock, outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statement [Table] Product and Service [Axis] Product and Service [Domain] Product [Member] Product revenue Statement [Line Items] Statement Revenue from Contract with Customer, Including Assessed Tax Total revenues Revenue Costs and Expenses [Abstract] Costs and expenses: Cost of Goods and Services Sold Cost of sales Research and Development Expense Research and development Selling, General and Administrative Expense Patent costs Selling, general, and administrative Operating Expenses Total costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other (expense) income: Other Nonoperating Income (Expense) Other income (expense), net Interest Expense Interest expense Investment Income, Interest Interest income Nonoperating Income (Expense) Total other (expense) income, net Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss before taxes Income Tax Expense (Benefit) Provision for income taxes Net loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding, basic (in shares) Other comprehensive loss: Other comprehensive loss: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Unrealized gain (loss), net on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common stock Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Sales in an at-the-market" offerings. At The Market Offerings [Member] At-the-market offering Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock compensation expense Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock in connection with ESPP Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock in connection with ESPP (in shares) The value of share options and vesting of stock units exercised during the current period. Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units Number of share options and vesting of stock units exercised during the current period. Stock Issued During Period Shares Stock Options And Restricted Stock Units Vesting Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) Equity impact of the value of new stock issued during the period from license agreement. Stock Issued During Period, Value, New Issues License Agreement Issuance of common stock as consideration for LGC license Equity issued in conjunction with license agreement Number of new stock issued during the period from license agreement. Stock Issued During Period, Shares, New Issues License Agreement Issuance of common stock as consideration for LGC license (in shares) Debt and Equity Securities, Gain (Loss) Net unrealized losses on short-term investments Stock Issued During Period, Value, New Issues Issuance of common stock, net of offering costs Issuance of stock Stock Issued During Period, Shares, New Issues Issuance of common stock, net of offering costs (in shares) Issuance of stock (in shares) Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Net unrealized loss on marketable securities Gain (Loss) on Contract Termination Reclassification of losses on RareStone equity into net loss Loss on RareStone equity investment CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense The aggregate expense charged against earnings for both property and equipment including intangible assets. DepreciationDepletionAndAmortizationPropertyAndEquipmentIncludingIntangibleAssets Depreciation and amortization Amount of Non-cash interest expense and amortization of debt issuance costs. Non cash Interest Expense And Amortization Of Debt Issuance Costs Non-cash interest expense and amortization of debt issuance costs Amount of non-cash accretion & amortization of short-term investments. Non cash Accretion And Amortization Of Short Term Investments Non-cash accretion & amortization of short-term investments Unrealized Gain (Loss) on Investments Unrealized loss on short-term investments The amount of non-cash accretion of non-current liability Non Cash Accretion Of Non-current liability Non-cash accretion of non-current liability Amount of deferred rent expense (reversal of expense). Deferred Rent Expense Non-cash rent expense Increase (Decrease) in Derivative Liabilities Change in fair value of embedded derivative liability The amount of acquired were In-Process Research and Development assets classified as investing activities. Acquired In-Process Research and Development Assets Classified as Investing Activities Acquired IPR&D assets classified as investing activities Increase (Decrease) in Operating Assets [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Other Noncurrent Assets Other long-term assets, net Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and other liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments to Acquire Short-term Investments Purchases of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-term Investments Maturities of short-term investments Payments to Acquire Intangible Assets Acquisition of IPR&D assets Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Repayments of Long-Term Debt Repayment of deferred royalty obligation Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Proceeds from Stock Plans Proceeds from issuance of common stock from ESPP Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rates on cash Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Supplemental disclosure of non-cash investing activities Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Non-current liability issued in exchange for the acquisition of IPR&D The value of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Value Shares Issued Issuance of common stock in exchange for IPR&D Nature of Business Nature of Operations [Text Block] Nature of Business Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Asset Acquisitions Asset Acquisition [Text Block] Asset Acquisitions Inventory Inventory Disclosure [Text Block] Inventory Accrued Expenses and Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses and Other Current Liabilities Fair Value of Financial Assets and Liabilities Fair Value Disclosures [Text Block] Fair Value of Financial Assets and Liabilities Right of Use Asset and Lease Liability Lessee, Operating Leases [Text Block] Right of Use Asset and Lease Liability Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Income Taxes Income Tax Disclosure [Text Block] Income Taxes Common Stock. Stockholders' Equity Note Disclosure [Text Block] Common Stock Related-Party Transactions Related Party Transactions Disclosure [Text Block] Related-Party Transactions Long-Term Obligations Debt Disclosure [Text Block] Long-Term Obligations Subsequent Events Subsequent Events [Text Block] Subsequent Events Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Consolidation, Policy [Policy Text Block] Principles of Consolidation Reclassification, Comparability Adjustment [Policy Text Block] Reclassification of Prior Year Balances Segment Reporting, Policy [Policy Text Block] Segment Information Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block] Off-Balance Sheet Risk and Concentrations of Credit Risk Accounts Receivable [Policy Text Block] Accounts Receivable, net Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Disclosure of accounting policy for License Agreements. License Agreements, Accounting Policy [Policy Text Block] License Agreements Disclosure of accounting policy for Deferred Royalty Obligation. Deferred Royalty Obligation, Accounting Policy [Policy Text Block] Deferred Royalty Obligation Inventory, Policy [Policy Text Block] Inventory Disclosure of accounting policy for cost of product sales. Cost Of Product Sales [Policy Text Block] Cost of Product Sales Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets, Net Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets and assessing and recognizing impairments of its property, plant and equipment. Impairment or Disposal of Long-Lived Assets And Property, Plant and Equipment [Policy Text Block] Impairment of Long-Lived Assets Disclosure of accounting policy for acquired finite lived intangibles Acquired Finite Lived Intangibles [Policy Text Block] Acquired IPR&D and Milestones Expenses Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Subsequent Events, Policy [Policy Text Block] Subsequent Events New Accounting Pronouncements, Policy [Policy Text Block] Application of New or Revised Accounting Standards Schedule of Inventory, Current [Table Text Block] Schedule of inventory Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Schedule of potential common shares, presented based on amounts outstanding at each period end, excluded from computation of diluted net loss per share attributable to common stockholders Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities measured at fair value on a recurring basis Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of fair value net derivative asset liability measured on recurring Basis Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of marketable securities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of operating lease maturities Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of finite-lived intangible assets Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Schedule of amortization expense Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Domain] Represents the information pertaining to Series A convertible preferred stock. Series A Convertible Preferred Stock [Member] Series A convertible preferred shares Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent events Class of Stock [Line Items] Common Stock Liquidity Cash, Cash Equivalents, and Short-term Investments Carrying amount of cash and cash equivalents and short term investments Share Price Price per share Inventory, Current [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer concentration risk Customer [Axis] Customer [Domain] Represents information pertaining to customer one. Customer One [Member] Customer one Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue Benchmark [Member] Revenue benchmark Inventory [Line Items] Summary of Significant Accounting Policies Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Segment Information Number of Operating Segments Number of operating segments Number of Reportable Segments Number of reporting segments No definition available. Off Balance Sheet Risk and Concentrations of Credit Risk [Abstract] Off Balance Sheet Risk and Concentrations of Credit Risk The number of federally insured financial institutions. Number of Federally Insured Financial Institutions Number of federally insured financial institutions Concentration Risk, Percentage Percentage of revenue generated from customer Tangible Asset Impairment Charges [Abstract] Impairment of Long-Lived Assets Tangible Asset Impairment Charges Tangible asset impairment charges No definition available. Patent Costs [Abstract] Patent Costs Receivables, Net, Current [Abstract] Accounts Receivable, net Receivables, Net, Current Accounts receivables Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information pertaining to license agreement and share issuance agreement. License Agreement And Share Issuance Agreement [Member] License agreement Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to the LG Chem Ltd. L G Chem Ltd [Member] L G Chem Ltd Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Significant Agreements Significant Agreements The amount of cash payment made for the agreement. Cash Payment Made For License Agreement Cash payment The amount of upfront consideration received in cash in license agreement. License Agreement Consideration Payment Received In Cash License agreement consideration payment The lock up period for subsequent cash payment in the agreement. Lock Up Period For Subsequent Cash Payment Effective date of the license agreement The number of patients be evaluated under the Signal trial. Number Of Patients Be Evaluated Under The Signal Trial Number of patients The number of doses participants will receive now under the signal trial. Number Of Doses Participants Will Receive Under The Signal Trial Number of doses participants The maximum number of doses participants will receive in the signal trial. Maximum Number of Doses Participants Will Receive in The Signal Trial Maximum number of doses participants The period for which participant will be receiving one dose of the medicine in the signal trial. Duration For Which Participant Will Be Receiving One Dose In The Signal Trial Period of oral administration The period to check the primary end point of the treatment in the signal trial. Duration to Check the Primary End Point Of the Treatment in the Signal Trial Period to check the primary end point of the treatment The period it takes for the route trial to complete the treatment. Duration for Route Trial Period of route trial The number of patients be enrolled under the route trial. Number of Patients be Enrolled Under the Route Trial Number of enrolled patients The amount of clinical development milestone payments. Clinical Development Milestone Payments Clinical development milestone payments The amount of regulatory approval and commercial milestone payments. Commercial Regulatory Approval and Milestone Payments Regulatory approval and commercial milestones milestone payments The amount of sales milestone payments. Sales Milestone Payments Sales milestone payments Business Combination, Acquisition Related Costs Acquisition related costs Represents information pertaining to RareStone Group Ltd. Rare Stone Group Ltd [Member] RareStone Group Ltd. Represents information pertaining to license agreement. License Agreement [Member] License agreement The number of performance obligations in license agreement. License Agreement, Number of Performance Obligations Number of performance obligations The amount of discount on commercial manufacturing supply in license agreement. License Agreement, Commercial Manufacturing Supply, Discount License agreement commercial manufacturing supply discount Amount of realized gain (loss) on investment in Rarestone valuation. Rarestone Valuation Realized Gain Loss Realized loss on RareStone equity The amount of upfront consideration received on license agreement. License Agreement, Upfront Consideration Upfront consideration Contract with Customer, Liability, Revenue Recognized Contract with customer liability revenue recognized The number of independent sub studies conducted in patients. Number Of Independent Sub Studies In Patients Number of independent sub studies in patients Represents the amount of an upfront payment. Upfront Payment Upfront payment Other Assets, Fair Value Disclosure Equity recorded at fair value Represent the amount of aggregate payment upon achievement of development and commercial milestones. Aggregate Payment Upon Achievement Of Development And Commercial Milestones Aggregate payment upon achievement of development and commercial milestones Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Restricted Stock Units (RSUs) [Member] Restricted stock units Performance Shares [Member] Performance stock units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares excluded from the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential common shares Asset Acquisition [Table] Represents information pertaining to Xinvento B.V. Xinvento B V [Member Xinvento B.V. Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and development Asset Acquisition [Line Items] Asset Acquisition Business Combination, Consideration Transferred Purchase consideration Payments to Acquire Businesses, Gross Cash consideration Accounts Payable, Fair Value Disclosure Present value The amount of holdback, payable on the one-year anniversary of the acquisition. Holdback, Payable on the One-year Anniversary of the Acquisition Holdback, payable on the one-year anniversary of the acquisition Inventory, Raw Materials and Supplies, Gross Raw Materials Inventory, Work in Process, Gross WIP Inventory, Finished Goods, Gross Finished Goods Amount of expenses incurred but not yet paid related to research and development, due within one year or the normal operating cycle, if longer. Accrued Research and Development Costs Research and development costs Accrued Professional Fees, Current Professional fees Amount of expenses incurred but not yet paid related to payroll, due within one year or the normal operating cycle, if longer. Accrued Payroll Related Expense Current Payroll related Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Royalties, Current Royalties Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales allowances. Sales Allowances Accrued, Current Sales Allowances Other Accrued Liabilities, Current Other Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Financial Instrument [Axis] Financial Instruments [Domain] Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment. Includes commercial paper. Corporate Debt Securities And Commercial Paper [Member] Corporate Debt Securities and Commercial Paper Money Market Funds [Member] Money Market Funds Liability Class [Axis] Fair Value by Liability Class [Domain] Derivative Financial Instruments, Liabilities [Member] Derivative on Royalty Financing Measurement Basis [Axis] Portion at Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Estimated fair value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Assets Assets, Fair Value Disclosure [Abstract] Fair value of financial assets and liabilities Cash and Cash Equivalents, Fair Value Disclosure Cash Equivalents Available-for-sale Securities, Amortized Cost Basis Marketable Securities Fair Value Assets, Fair Value Disclosure Fair value of assets Embedded Derivative [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information pertaining to revenue interest financing agreement. Revenue Interest Financing Agreement [Member] Revenue Interest Financing Agreement Embedded Derivative [Line Items] Fair value of embedded derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Ending aggregate estimated fair value of Level 3 liabilities Beginning aggregate estimated fair value of Level 3 liabilities Fair value of embedded derivative liability Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Change in fair value of embedded derivative Remeasurement of the embedded derivative liability Available-for-sale Securities, Current Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Lessee, Operating Lease, Remaining Lease Term Remaining term of operating lease (in years) Lessee, Operating Lease, Discount Rate Operating lease discount rate Lessee, Operating Lease, Term of Contract Lease term (in years) Lessee, Operating Lease, Renewal Term Lease renewal term (in years) Lessee, Operating Lease, Existence of Option to Extend [true false] Option to extend Lessee, Operating Lease, Liability, Payment, Due [Abstract] Right of Use Asset and Lease Liability Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2024 Lessee, Operating Lease, Liability, Payments, Due Year Two 2025 Lessee, Operating Lease, Liability, Payments, Due Total operating lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Operating Lease, Liability Total operating lease liability Schedule of Finite-Lived Intangible Assets [Table] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Information pertaining to capitalized milestones. Capitalized Milestones [Member] Capitalized Milestones Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets Finite-Lived Intangible Asset, Useful Life Estimated life (years) Finite-Lived Intangible Assets, Gross Cost Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Cost of Sales [Member] Cost of sales Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Definite-lived intangible assets Finite-Lived Intangible Asset, Expected Amortization, Year One 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2025 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2026 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2027 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2028 Finite-Lived Intangible Assets, Amortization Expense, after Year Five Thereafter Amortization of Intangible Assets Amortization expense Foreign Income Tax Expense (Benefit), Continuing Operations Foreign income tax provision Asset Acquisition [Axis] Asset Acquisition [Domain] Represents the information pertaining to the rights of compound LB54640. Rights of Compound L B 54640 [Member] Rights of compound L B 54640 Range [Axis] Range [Domain] Maximum [Member] Maximum Preferred Stock [Member] Preferred stock Equity Option [Member] Equity Option Plan Name [Axis] Plan Name [Domain] Represents the information pertaining to 2017 employee stock purchase plan (ESPP). Two Thousand Seventeen Employee Stock Purchase Plan [Member] 2017 Employee Stock Purchase Plan Information regarding the 2022 Employment Inducement Plan. Employment Inducement Plan 2022 [Member] 2022 Employment Inducement Plan Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for issuance Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for future grant Sale of Stock, Consideration Received on Transaction Aggregate proceeds Schedule of Related Party Transactions, by Related Party [Table] Consultants and vendors of the Company. Consultants And Vendors [Member] Consultants and vendors Balance Sheet Location [Axis] Balance Sheet Location [Domain] Accounts Payable [Member] Accounts payable Related Party Transaction [Line Items] Related-Party Transactions Affiliate Costs Net costs Due to Affiliate Due to related party Schedule of Long-Term Debt Instruments [Table] Minimum [Member] Minimum Scenario [Axis] Scenario, Unspecified [Domain] Represents information pertaining to annual net revenues up to $125 million. Annual Net Revenues Up To 125 Million [Member] Annual net revenues up to 125 million Represents information pertaining to annual net revenues between $125 million and $300 million. Annual Net Revenues Between 125 Million And 300 Million [Member] Annual net revenues between 125 million and 300 million Represents information pertaining to annual net revenues exceeding $300 million. Annual Net Revenues Exceeding 300 Million [Member] Annual net revenues exceeding 300 million Represents information pertaining to cumulative minimum payments threshold date March 31, 2027. Cumulative Minimum Payments Funding Threshold Date March 31 2027 [Member] March 31, 2027 Represents information pertaining to cumulative minimum payments threshold date March 31, 2029. Cumulative Minimum Payments Funding Threshold Date March 31 2029 [Member] March 31, 2029 Debt Instrument [Line Items] Long-Term Obligations Debt Instrument, Face Amount Aggregate investment amount The cash inflow from the royalty financing agreement, net of issuance costs. Proceeds From Royalty Financing Agreement Remaining Investment Amount The percent of royalty interest payment on annual net revenues, payable to investors. Percent of Royalty Interest Payment on Annual Net Revenues Royalty interest (as a percent) The amount of threshold annual net sales for calculating revenue interest. Threshold Annual Net Revenues for Royalty Interest Threshold annual net revenues The threshold percentage of cumulative minimum payments to be funded to investors, the failure of which would require cash payment immediately following each applicable date to the Investors sufficient to gross the Investors up to such minimum amounts after giving full consideration of the cumulative amounts paid by to the Investors through each date, referred to as the Under Performance Payment. Threshold Percent of Cumulative Minimum Payments Funding to Investors Threshold cumulative minimum payments (as a percent) Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Repayment of debt Proceeds from (Repayments of) Long-Term Debt and Capital Securities Cumulative repayment of debt The percent of total revenue interests payable cap as a percent of investment amount. Revenue Interests Payable Cap as Percent of Investment Amount Revenue interest cap (as a percent) The period within which the hard cap of initial investment amount to be received by investors. Revenue Interest Payment, Period from Initial Closing Revenue interest payment period Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Debt Issuance Costs, Net Debt issuance costs Subsequent Event [Table] Subsequent Event [Line Items] Subsequent events The limited the voting rights of the Convertible Preferred Stock to the shares of the Company's common stock. Limited Voting Rights, Shares Limited voting rights of convertible preferred stock to common stock shares Amount of liquidation preference of Convertible Preferred Stock. Liquidation Preference Liquidation preference of convertible preferred stock Step up interest rate. Step Up Interest Rate, Percentage Step up interest rate Percentage of certain investors and certain of their affiliated entities before stock transaction. Investors And Affiliated Entities, Percentage of Ownership before Transaction Percentage of certain investors and certain of their affiliated entities before stock transaction Duration of time milestone payments are not expected to be paid to third parties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter. Duration Milestone Payments Not Expecting To Be Paid Duration of time milestone payments are not expected to be paid to third parties